Show simple item record

dc.contributor.authorHoran, Martin Patrick
dc.contributor.authorChai, Sze Yee
dc.contributor.authorMunusamy, Nalishia
dc.contributor.authorTay, Kwang Hong
dc.contributor.authorWienholt, Louise
dc.contributor.authorTye-Din, Jason A
dc.contributor.authorDaveson, James
dc.contributor.authorVarney, Michael
dc.contributor.authorBadrick, Tony
dc.date.accessioned2020-02-17T01:02:25Z
dc.date.available2020-02-17T01:02:25Z
dc.date.issued2018
dc.identifier.issn0021-9746
dc.identifier.doi10.1136/jclinpath-2018-205209
dc.identifier.urihttp://hdl.handle.net/10072/391540
dc.description.abstractAim: Coeliac disease(CD) is a highly prevalent, gluten-dependent, autoimmune enteropathy. While the diagnosis is based on serological and histological criteria, genotyping of the human leucocyte antigens (HLA) DQ2 and DQ8 has been shown to have substantial clinical utility, especially in excluding the diagnosis in patients who do not carry either antigen. As a result, HLA genotyping is now being performed by more laboratories and has recently become one of the most frequently requested genetic tests in Australia. To date, there has been little scrutiny on the accuracy and reporting of results by laboratories new to HLA typing. In response to clinician feedback that identified potentially clinically significant discrepancies in HLA typing results, the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) undertook a pilot study to assess laboratory performance in the detection of HLA-DQ2/DQ8 and their associated HLA-DQA1 and HLA-DQB1 alleles. Methods: DNA was extracted from 5 patients and sent to 10 laboratories for external quality assurance (EQA) testing. Laboratories were assessed for reporting in genotyping, interpretation and methodology. Results: Our findings showed that at least 80% of laboratories underperform with respect to recommended guidelines for HLA typing and reporting for CD, with 40% of laboratories failing to provide any clinical interpretation or full genotyping data. This suboptimal level of reporting may lead to ambiguities for downstream clinical interpretation that may compromise patient management. Conclusions: These findings highlight the importance of adherence to standardised guidelines for optimal performance and reporting of HLA results and substantiate the need for EQA and proficiency testing for laboratories providing this service.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBMJ Publishing Group Ltd
dc.relation.ispartofpagefrom900
dc.relation.ispartofpageto905
dc.relation.ispartofissue10
dc.relation.ispartofjournalJournal of Clinical Pathology
dc.relation.ispartofvolume71
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchMedical microbiology
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3207
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPathology
dc.subject.keywordsGUIDELINES
dc.subject.keywordsDIAGNOSIS
dc.titleHigh rates of variation in HLA-DQ2/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationHoran, MP; Chai, SY; Munusamy, N; Tay, KH; Wienholt, L; Tye-Din, JA; Daveson, J; Varney, M; Badrick, T, High rates of variation in HLA-DQ2/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program, Journal of Clinical Pathology, 2018, 71 (10), pp. 900-905
dcterms.dateAccepted2018-04-30
dc.date.updated2020-02-17T00:59:43Z
gro.hasfulltextNo Full Text
gro.griffith.authorBadrick, Tony C.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record